Two days ago the U.S. Supreme Court said pharma companies can be sued for pay-for-delay deals, and now the European Commission has fined Lundbeck and a cadre of companies €146 million ($195.5 million) for the same thing.
Now that Obamacare has had its day at the Supreme Court, pharma has another case to worry about. The longstanding debate over "pay-for-delay" deals with generics companies could soon make its way to the high court, legal experts say. And if it does, branded drugmakers and generics companies would face a wholesale shift in their business strategies.
A federal appeals court pulled a pay-to-delay challenge out of mothballs, forcing Merck to fight claims that its Schering-Plough unit delayed generic versions of its potassium drug K-Dur. But Merck isn't the only drugmaker that should keep an eye on this case.
AstraZeneca took another shot at stopping generic Seroquel--and lost, at least so far.
The pay-for-delay battle is now in U.K. court. Health Secretary Andrew Lansley has sued the French drugmaker Servier for £220 million ($361.3 million), claiming that the company blocked generic
After an 18-month probe, E.U. antitrust regulators say they're embarking on a campaign for sweeping change in the pharma business. Generics take too long to get to market, they say, an average of
Forces are aligning against "pay-for-delay" patent settlements. After years of pooh-poohing the Federal Trade Commission's fight against the deals, the U.S. Justice Department now has signed up for
Would you like to save $35 billion on healthcare? Trick question, right? Put the words "save" and "billion" and "healthcare" in the same sentence these days, and you'll probably get a call from
The U.S. Supreme Court passed on a chance to check out "pay for delay" deals between drugmakers and generics firms. Bad news for critics of those deals, which happen to include the federal
U.S. District Judge Ricardo Urbina apparently believes the old adage that everyone has at least one book in them. Judge Urbina sentenced a former Bristol-Myers Squibb exec to write one--in penance